U.S. Cancer Treatment Market - Industry Trends and Forecast to 2029
- Published Date: 2022-11-22
- Report ID: 144258
- Pages: 200
-
Format:
Short Description
U.S. Cancer Treatment Market, By Cancer Type (Breast Cancer, Colorectal Cancer with Liver Metastases, Lung Carcinoma, Prostate Cancer, Ovarian Cancer, Head-And-Neck Cancer, Pancreatic Cancer, Glioblastoma, Renal Cell Carcinoma, Anaplastic Thyroid Carcinoma, Sarcoma, and Others), Treatment (Medication, Targeted Therapies, Radiotherapy, Surgery, and Others), Route of Administration (Injectable, Oral, and Others), End User (Hospitals, Specialty Clinics), Country (U.S.) - Industry Trends and Forecast to 2029
Market Definition:
Cancer is a disease in which some of the body's cells grow uncontrollably and eventually spread to other parts of the body. The cancerous tumor spreads to nearby tissues and can travel to distant places within the body to form a new tumor. This process is called metastases. The cancerous tumor is also referred to as a malignant tumor. The benign tumor does not invade nearby tissues, and when removed, benign tumors usually don't grow back, whereas cancerous tumors sometimes do.
There are more than a hundred types of cancer. Some cancers that begin in specific types of cells include carcinoma, sarcoma, leukemia, lymphoma, and multiple myeloma, among others. Many types of cancer are available based on the type of cancer treatments. Cancer treatment includes biomarker testing, chemotherapy, hormone therapy, hyperthermia, immunotherapy, photodynamic therapy, radiation therapy, surgery, stem cell transplant, and targeted therapies.
According to GLOBOCAN, 19,292,789 new cancer cases were found in 2020 worldwide. The highest cases of breast cancer were found. Therefore, the high prevalence of cancer, initiatives taken by the government for awareness and early detection of cancer, and ongoing clinical trials are expected to fuel the market's growth.
Market Segmentation:
The U.S. cancer treatment market is categorized into four notable segments based on cancer type, treatment, route of administration, and end user.
On the basis of cancer type, the U.S. cancer treatment market is segmented into breast cancer, colorectal cancer with liver metastases, lung carcinoma, prostate cancer, ovarian cancer, head-and-neck cancer, pancreatic cancer, glioblastoma, renal cell carcinoma, anaplastic thyroid carcinoma, and sarcoma
On the basis of treatment, the U.S. cancer treatment market is segmented into medication, targeted therapies, radiotherapy, surgery, and others
On the basis of route of administration, the U.S. cancer treatment market is segmented into injectable, oral, and others
On the basis of end user, the U.S. cancer treatment market is segmented into hospitals and specialty clinics
Market Players
Some of the major companies dealing in the U.S. cancer treatment market are listed below:
Bristol-Myers Squibb Company
F. Hoffman La-Roche Ltd.
Clegen
AbbVie, Inc.
Pfizer, Inc.
Novartis AG
TABLE OF CONTENTS
1 INTRODUCTION 17
1.1 OBJECTIVES OF THE STUDY 17
1.2 MARKET DEFINITION 17
1.3 OVERVIEW OF U.S. CANCER TREATMENT MARKET 17
1.4 LIMITATIONS 19
1.5 MARKETS COVERED 20
2 MARKET SEGMENTATION 25
2.1 MARKETS COVERED 25
2.2 GEOGRAPHICAL SCOPE 26
2.3 YEARS CONSIDERED FOR THE STUDY 26
2.4 CURRENCY AND PRICING 26
2.5 DBMR TRIPOD DATA VALIDATION MODEL 27
2.6 MULTIVARIATE MODELLING 30
2.7 CANCER TYPE LIFELINE CURVE 31
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 32
2.9 SECONDARY SOURCES 33
2.10 ASSUMPTIONS 33
3 EXECUTIVE SUMMARY 34
4 PREMIUM INSIGHTS 36
4.1 PESTEL ANALYSIS 37
4.2 PORTERS FIVE FORCES 38
5 EPIDEMOLOGY 39
6 U.S. CANCER TREATMENT MARKET: REGULATORY SCENARIO 42
6.1 TIMELINE TO APPROVE A DRUG 42
7 MARKET OVERVIEW 44
7.1 DRIVERS 46
7.1.1 GROWING CANCER BURDEN WORLDWIDE 46
7.1.2 GROWING GERIATRIC POPULATION 48
7.1.3 AVAILABILITY OF DIFFERENT TYPES OF TARGETED THERAPIES 50
7.1.4 RISING NUMBER OF FDA APPROVAL 50
7.1.5 GROWING R&D ACTIVITIES 51
7.2 RESTRAINTS 51
7.2.1 ADVERSE EFFECTS AND RISKS ASSOCIATED WITH CANCER TREATMENT DRUGS 51
7.2.2 HIGH COST OF CANCER TREATMENT 52
7.2.3 LACK OF EARLY DETECTION 52
7.3 OPPORTUNITIES 53
7.3.1 STRATEGIC DEVELOPMENT AMONG MAJOR PLAYERS 53
7.3.2 INCREASING INITIATIVES BY GOVERNMENT AND OTHER HEALTHCARE ORGANIZATIONS 54
7.3.3 RISING EXPENDITURE ON CANCER TREATMENT 55
7.4 CHALLENGES 55
7.4.1 PATENT EXPIRY OF DRUGS 55
8 U.S. CANCER TREATMENT MARKET, BY CANCER TYPE 57
8.1 OVERVIEW 58
8.2 BREAST CANCER 62
8.3 COLORECTAL CANCER WITH LIVER METASTASES 62
8.4 LUNG CARCINOMA 62
8.5 PROSTATE CANCER 63
8.6 OVARIAN CANCER 63
8.7 HEAD-AND-NECK CANCER 64
8.8 PANCREATIC CANCER 64
8.9 GLIOBLASTOMA 64
8.10 RENAL CELL CARCINOMA 65
8.11 ANAPLASTIC THYROID CARCINOMA 65
8.12 SARCOMA 66
9 U.S. CANCER TREATMENT MARKET, BY TREATMENT 67
9.1 OVERVIEW 68
9.2 MEDICATION 71
9.2.1 BY DRUG TYPE 71
9.2.1.1 LUNG CARCINOMA 72
9.2.1.1.1 NIVOLUMAB (OPDIVO) 73
9.2.1.1.2 BEVACIZUMAB (AVASTIN) 73
9.2.1.1.3 CRIZOTINIB (XALKORI) 73
9.2.1.1.4 ERLOTINIB (TARCEVA) 73
9.2.1.1.5 GEFITINIB (IRESSA) 73
9.2.1.1.6 AFATINIB DIMALEATE (GILOTRIF) 74
9.2.1.1.7 CERITINIB (LDK378/ZYKADIA) 74
9.2.1.1.8 RAMUCIRUMAB (CYRAMZA) 74
9.2.1.1.9 OTHERS 74
9.2.1.2 COLORECTAL CANCER WITH LIVER METASTASES 74
9.2.1.2.1 NIVOLUMAB (OPDIVO) 75
9.2.1.2.2 CETUXIMAB (ERBITUX) 75
9.2.1.2.3 PANITUMUMAB (VECTIBIX) 75
9.2.1.2.4 BEVACIZUMAB (AVASTIN) 75
9.2.1.2.5 ZIV-AFLIBERCEPT (ZALTRAP) 75
9.2.1.2.6 REGORAFENIB (STIVARGA) 76
9.2.1.2.7 RAMUCIRUMAB (CYRAMZA) 76
9.2.1.2.8 IPILIMUMAB (YERVOY) 76
9.2.1.2.9 ENCORAFENIB (BRAFTOVI) 76
9.2.1.2.10 PEMBROLIZUMAB (KEYTRUDA) 76
9.2.1.2.11 OTHERS 76
9.2.1.3 OVARIAN CANCER 77
9.2.1.3.1 BEVACIZUMAB (AVASTIN) 77
9.2.1.3.2 OLAPARIB (LYNPARZA) 77
9.2.1.3.3 RUCAPARIB CAMSYLATE (RUBRACA) 77
9.2.1.3.4 NIRAPARIB TOSYLATE MONOHYDRATE (ZEJULA) 77
9.2.1.3.5 OTHERS 77
9.2.1.4 HEAD-AND-NECK CANCER 78
9.2.1.4.1 CETUXIMAB (ERBITUX) 78
9.2.1.4.2 PEMBROLIZUMAB (KEYTRUDA) 78
9.2.1.4.3 NIVOLUMAB (OPDIVO) 78
9.2.1.4.4 OTHERS 78
9.2.1.5 RENAL CELL CARCINOMA 78
9.2.1.5.1 NIVOLUMAB (OPDIVO) 79
9.2.1.5.2 BEVACIZUMAB (AVASTIN) 79
9.2.1.5.3 SORAFENIB (NEXAVAR) 79
9.2.1.5.4 SUNITINIB (SUTENT) 79
9.2.1.5.5 PAZOPANIB (VOTRIENT) 79
9.2.1.5.6 TEMSIROLIMUS (TORISEL) 80
9.2.1.5.7 EVEROLIMUS (AFINITOR) 80
9.2.1.5.8 AXITINIB (INLYTA) 80
9.2.1.5.9 CABOZANTINIB (CABOMETYX) 80
9.2.1.5.10 OTHERS 80
9.2.1.6 ANAPLASTIC THYROID CARCINOMA 81
9.2.1.6.1 CABOZANTINIB (COMETRIQ) 81
9.2.1.6.2 VANDETANIB (CAPRELSA) 81
9.2.1.6.3 SORAFENIB (NEXAVAR) 81
9.2.1.6.4 LENVATINIB MESYLATE (LENVIMA) 81
9.2.1.6.5 TRAMETINIB (MEKINIST) 82
9.2.1.6.6 DABRAFENIB (TAFINLAR) 82
9.2.1.6.7 SELPERCATINIB (RETEVMO) 82
9.2.1.6.8 PRALSETINIB (GAVRETO) 82
9.2.1.6.9 OTHERS 82
9.2.1.7 BREAST CANCER 83
9.2.1.7.1 EVEROLIMUS (AFINITOR) 83
9.2.1.7.2 TAMOXIFEN (NOLVADEX) 83
9.2.1.7.3 TRASTUZUMAB (HERCEPTIN) 84
9.2.1.7.4 FULVESTRANT (FASLODEX) 84
9.2.1.7.5 ANASTROZOLE (ARIMIDEX) 84
9.2.1.7.6 EXEMESTANE (AROMASIN) 84
9.2.1.7.7 LETROZOLE (FEMARA) 84
9.2.1.7.8 PERTUZUMAB (PERJETA) 84
9.2.1.7.9 PALBOCICLIB (IBRANCE) 84
9.2.1.7.10 RIBOCICLIB (KISQALI) 84
9.2.1.7.11 TOSYLATE (TALZENNA) 85
9.2.1.7.12 PEMBROLIZUMAB (KEYTRUDA) 85
9.2.1.7.13 MARGETUXIMAB-CMKB (MARGENZA) 85
9.2.1.7.14 OTHERS 85
9.2.1.8 PROSTATE CANCER 85
9.2.1.8.1 CABAZITAXEL (JEVTANA) 86
9.2.1.8.2 ENZALUTAMIDE (XTANDI) 86
9.2.1.8.3 ABIRATERONE ACETATE (ZYTIGA) 86
9.2.1.8.4 RADIUM 223 DICHLORIDE (XOFIGO) 86
9.2.1.8.5 APALUTAMIDE (ERLEADA) 86
9.2.1.8.6 DAROLUTAMIDE (NUBEQA) 86
9.2.1.8.7 RUCAPARIB CAMSYLATE (RUBRACA) 86
9.2.1.8.8 OLAPARIB (LYNPARZA) 86
9.2.1.8.9 OTHERS 86
9.2.1.9 PANCREATIC CANCER 87
9.2.1.9.1 ERLOTINIB (TARCEVA) 87
9.2.1.9.2 EVEROLIMUS (AFINITOR) 87
9.2.1.9.3 SUNITINIB (SUTENT) 87
9.2.1.9.4 OLAPARIB (LYNPARZA) 87
9.2.1.9.5 BELZUTIFAN (WELIREG) 88
9.2.1.9.6 OTHERS 88
9.2.1.10 GLIOBLASTOMA 88
9.2.1.10.1 BEVACIZUMAB (AVASTIN) 88
9.2.1.10.2 EVEROLIMUS (AFINITOR) 88
9.2.1.10.3 BELZUTIFAN (WELIREG) 88
9.2.1.10.4 OTHERS 89
9.2.1.11 SARCOMA 89
9.2.1.11.1 COSMEGEN (DACTINOMYCIN) 89
9.2.1.11.2 DACTINOMYCIN 89
9.2.1.11.3 DOXORUBICIN HYDROCHLORIDE 90
9.2.1.11.4 ERIBULIN MESYLATE 90
9.2.1.11.5 GLEEVEC (IMATINIB MESYLATE) 90
9.2.1.11.6 HALAVEN (ERIBULIN MESYLATE) 90
9.2.1.11.7 IMATINIB MESYLATE 90
9.2.1.11.8 PAZOPANIB HYDROCHLORIDE 90
9.2.1.11.9 TAZEMETOSTAT HYDROBROMIDE 90
9.2.1.11.10 TAZVERIK (TAZEMETOSTAT HYDROBROMIDE) 90
9.2.1.11.11 TRABECTEDIN 90
9.2.1.11.12 VOTRIENT (PAZOPANIB HYDROCHLORIDE) 91
9.2.1.11.13 YONDELIS (TRABECTEDIN) 91
9.2.1.11.14 OTHERS 91
9.2.2 BY VACCINES 91
9.2.2.1 CERVARIX 91
9.2.2.2 GARDASIL 91
9.2.2.3 GARDASIL-9 91
9.2.2.4 HEPATITIS B (HBV) VACCINE (HEPLISAV-B) 92
9.2.2.5 SIPULEUCEL-T (PROVENGE) 92
9.2.2.6 OTHERS 92
9.3 RADIOTHERAPY 92
9.3.1 EXTERNAL BEAM RADIATION THERAPY 93
9.3.1.1 THREE -DIMENSIONAL CONFROMAL RADIATION THERAPY (3-D CRT) 93
9.3.1.2 PROTON THERAPY 93
9.3.1.3 INTENSITY-MODULATED RADIATION THERAPY (IMRT) 93
9.3.1.4 IMAGE-GUIDED RADIATION THERAPY (IGRT) 94
9.3.1.5 TOMOTHERAPY 94
9.3.1.6 STEREOTACIC RADIOSURGERY 94
9.3.1.7 STEREOTACTIC BODY RADIATION THERAPY (SRT) 94
9.3.1.8 INTRAOPERATIVE RADIATION THERAPY 94
9.3.1.9 OTHERS 94
9.3.2 INTERNAL RADIATION THERAPY (BRACHYTHERAPY) 94
9.3.2.1 LOW-DOSE-RATE (LDR) BRACHYTHERAPY 95
9.3.2.2 HIGH-DOSE-RATE (HDR) BRACHYTHERAPY 95
9.3.3 SYSTEMIC RADIATION THERAPY 95
9.3.3.1 PEPTIDE RECEPTOR RADIONUCLIDE THERAPY (PRRT) 95
9.3.3.2 OTHERS 95
9.4 SURGERY 95
9.4.1 PAROTIDECTOMY 96
9.4.2 ENDOSCOPIC SURGERY 96
9.4.3 NECK DISSECTION 96
9.4.4 RECONSTRUCTIVE SURGERY 96
9.4.5 OTHERS 96
9.5 TARGETED THERAPIES 96
9.5.1 SMALL MOLECULES 97
9.5.1.1 TYROSINE & SERINE/THREONINE KINASES 98
9.5.1.1.1 IMATINIB (GLEEVEC) 98
9.5.1.1.2 GEFITINIB (IRESSA) 98
9.5.1.1.3 ERLOTINIB (TARCEVA) 98
9.5.1.1.4 SUNITINIB (SUTENT) 98
9.5.1.1.5 PERIFOSINE 99
9.5.1.1.6 OTHERS 99
9.5.1.2 PROTEOSOMES 99
9.5.1.2.1 BORTEZOMIB (VELCADE) 99
9.5.1.2.2 CARFILZOMIB (KYPROLIS) 99
9.5.1.2.3 MARIZOMIB 99
9.5.1.3 MMPS AND HSPS 100
9.5.1.3.1 BATIMASTAT 100
9.5.1.3.2 NEOVASTAT 100
9.5.1.3.3 PRINOMASTAT 100
9.5.1.3.4 REBIMASTAT 100
9.5.1.3.5 GANETESPIB 100
9.5.1.3.6 OTHERS 101
9.5.1.4 APOPTOSIS 101
9.5.1.4.1 OBATOCLAX 101
9.5.1.4.2 NAVITOCLAX 101
9.5.1.4.3 OTHERS 101
9.5.2 IMMUNOTHERAPY 101
9.5.2.1 IMMUNE CHECKPOINT INHIBITORS 102
9.5.2.2 T-CELL TRANSFER THERAPY 102
9.5.2.2.1 TIL THERAPY 103
9.5.2.2.2 CAR T-CELL THERAPY 103
9.5.2.2.3 BY PRODUCT 103
9.5.2.2.3.1 TISAGENLECLEUCEL (KYMRIAH) 103
9.5.2.2.3.2 AXICABTAGENE CILOLEUCEL (YESCARTA) 103
9.5.2.2.3.3 BREXUCABTAGENE AUTOLEUCEL (TECARTUS) 103
9.5.2.2.3.4 OTHERS 104
9.5.2.2.4 BY TECHNOLOGY 104
9.5.2.2.4.1 AUTOLOGOUS 104
9.5.2.2.4.2 ALLOGENEIC 104
9.5.2.3 MONOCLONAL ANTIBODIES 104
9.5.2.3.1 RITUXIMAB 105
9.5.2.3.2 BLINATUMOMAB (BLINCYTO) 105
9.5.2.3.3 OTHERS 105
9.5.2.4 IMMUNE SYSTEM MODULATORS 105
9.5.2.4.1 CYTOKINES 106
9.5.2.4.2 INTERFERONS (INFS) 106
9.5.2.4.3 INTERLEUKINS (ILS) 106
9.5.2.4.4 HEMATOPOIETIC GROWTH FACTORS 106
9.5.2.4.5 BCG 106
9.5.2.4.6 IMMUNOMODULATORY DRUGS/BIOLOGICAL RESPONSE MODIFIER 107
9.5.2.4.7 THALIDOMIDE (THALOMID) 107
9.5.2.4.8 LENALIDOMIDE (REVLIMID) 107
9.5.2.4.9 POMALIDOMIDE (POMALYST) 107
9.5.2.4.10 IMIQUIMOD (ALDARA, ZYCLARA) 107
9.5.2.4.11 OTHERS 107
9.5.2.5 TREATMENT VACCINES 107
9.5.2.6 OTHERS 107
9.5.3 HORMONAL THERAPY 107
9.5.3.1 SIGNAL TRANSDUCTION INHIBITORS 108
9.5.3.2 GENE EXPRESSION MODULATORS 108
9.5.3.3 APOPTOSIS INDUCERS 108
9.5.3.4 ANGIOGENESIS INHIBITORS 108
9.5.3.5 GENE THERAPY 108
9.5.3.6 OTHERS 108
9.6 OTHERS 109
10 U.S. CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 110
10.1 OVERVIEW 111
10.2 INJECTABLE 114
10.3 ORAL 114
10.4 OTHERS 114
11 U.S. CANCER TREATMENT MARKET, BY END USER 115
11.1 OVERVIEW 116
11.2 HOSPITALS 119
11.3 SPECIALTY CLINICS 119
12 U.S. CANCER TREATMENT MARKET, BY COUNTRY 120
12.1 U.S. 120
13 QUESTIONNAIRE 135
14 RELATED REPORTS 138
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
